Current Report Filing (8-k)
March 10 2021 - 4:06PM
Edgar (US Regulatory)
0001083446
false
0001083446
2021-03-10
2021-03-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
March 10, 2021
APOLLO MEDICAL HOLDINGS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-37392
|
|
95-4472349
|
(State or Other Jurisdiction
|
|
(Commission File
|
|
(I.R.S. Employer
|
of Incorporation)
|
|
Number)
|
|
Identification Number)
|
1668 S. Garfield Avenue, 2nd Floor, Alhambra,
CA 91801
(Address of principal executive offices)
(zip code)
(626) 282-0288
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Precommencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Precommencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
AMEH
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02
|
Results of Operations and Financial Condition.
|
On March 10, 2021,
Apollo Medical Holdings, Inc. (the “Company”) issued a press release announcing its financial results for
the quarter and year ended December 31, 2020. The Company is also making available certain supplemental data for the quarter and
year ended December 31, 2020. A copy of the press release and supplemental data are attached hereto as Exhibit 99.1 and 99.2, respectively,
and incorporated herein by this reference.
In accordance with
General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 2.02, including Exhibit 99.1 and Exhibit 99.2
furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
|
Financial Statements and Exhibits
|
(d)
Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
APOLLO MEDICAL HOLDINGS, INC.
|
|
|
Dated: March 10, 2021
|
By:
|
/s/ Thomas S. Lam
|
|
Name:
|
Thomas S. Lam,
M.D., M.P.H.
|
|
Title:
|
Co-Chief Executive Officer and President
|
Apollo Medical (NASDAQ:AMEH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apollo Medical (NASDAQ:AMEH)
Historical Stock Chart
From Apr 2023 to Apr 2024